Presentations and webcasts

Register for our Alert Service to be notified whenever we add a presentation to our site.

Title Press Release Powerpoint Webcast
AGM Presentation  pdf 2012blue pdf 2012blue
2015/16 Results Webcast
pdf 2012blue

pdf 2012blue
Interim Results 31 Dec 2015 pdf 2012blue pdf 2012blue Webcast
Moxatag Acquisition  
pdf 2012blue
pdf 2012blue
2014/15 Results Webcast  pdf 2012blue  pdf 2012blue  
Tuzistra Approval   pdf 2012blue


H2 Interim Results Dec 2014  pdf 2012blue  


Interim Results June 2014 Webcast    


2013 Results Webcast    


Interim Results 2013 Webcast    


2012 Results Webcast    


Interim Results 2012 webcast    


Note: To view PDF files, you will need the Adobe Acrobat Reader. This can be downloaded free of charge from the Adobe website.

Latest News

FDA accepts CCP-08 NDA for full review

Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug Administration ("FDA") has accepted the CCP-08 New Drug Application ("NDA") for full review. This triggers a milestone payment from Vernalis to Tris. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and or FDA at 1-800-FDA-1088 or